JP2008508298A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008508298A5 JP2008508298A5 JP2007523776A JP2007523776A JP2008508298A5 JP 2008508298 A5 JP2008508298 A5 JP 2008508298A5 JP 2007523776 A JP2007523776 A JP 2007523776A JP 2007523776 A JP2007523776 A JP 2007523776A JP 2008508298 A5 JP2008508298 A5 JP 2008508298A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- cancer
- disease
- pharmaceutical composition
- sarcoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 16
- 206010028980 Neoplasm Diseases 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 14
- 239000003112 inhibitor Substances 0.000 claims 12
- 206010039491 Sarcoma Diseases 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 10
- 239000004480 active ingredient Substances 0.000 claims 9
- 230000001684 chronic effect Effects 0.000 claims 7
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 6
- 206010016654 Fibrosis Diseases 0.000 claims 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 6
- 206010060862 Prostate cancer Diseases 0.000 claims 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 6
- 208000025865 Ulcer Diseases 0.000 claims 6
- 108091008605 VEGF receptors Proteins 0.000 claims 6
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims 6
- 229940111134 coxibs Drugs 0.000 claims 6
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 230000004761 fibrosis Effects 0.000 claims 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 6
- 206010023332 keratitis Diseases 0.000 claims 6
- 229940043355 kinase inhibitor Drugs 0.000 claims 6
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 6
- 231100000397 ulcer Toxicity 0.000 claims 6
- 208000003174 Brain Neoplasms Diseases 0.000 claims 5
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 4
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 4
- 208000034578 Multiple myelomas Diseases 0.000 claims 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 4
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 4
- 239000003098 androgen Substances 0.000 claims 4
- 210000004369 blood Anatomy 0.000 claims 4
- 239000008280 blood Substances 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 208000005017 glioblastoma Diseases 0.000 claims 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 4
- 208000015181 infectious disease Diseases 0.000 claims 4
- 201000001441 melanoma Diseases 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims 3
- CQOQDQWUFQDJMK-SSTWWWIQSA-N 2-methoxy-17beta-estradiol Chemical group C([C@@H]12)C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CCC1=C2C=C(OC)C(O)=C1 CQOQDQWUFQDJMK-SSTWWWIQSA-N 0.000 claims 3
- 208000011231 Crohn disease Diseases 0.000 claims 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 3
- 108010036949 Cyclosporine Proteins 0.000 claims 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108010008165 Etanercept Proteins 0.000 claims 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 3
- 102000009465 Growth Factor Receptors Human genes 0.000 claims 3
- 108010009202 Growth Factor Receptors Proteins 0.000 claims 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 3
- 239000003458 I kappa b kinase inhibitor Substances 0.000 claims 3
- 102000004877 Insulin Human genes 0.000 claims 3
- 108090001061 Insulin Proteins 0.000 claims 3
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims 3
- 101710184277 Insulin-like growth factor 1 receptor Proteins 0.000 claims 3
- 108010002350 Interleukin-2 Proteins 0.000 claims 3
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 claims 3
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 3
- 229940119534 Lysophosphatidic acid acyltransferase inhibitor Drugs 0.000 claims 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 3
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 claims 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 3
- 108091033399 Telomestatin Proteins 0.000 claims 3
- 206010052779 Transplant rejections Diseases 0.000 claims 3
- 229940124674 VEGF-R inhibitor Drugs 0.000 claims 3
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 3
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 3
- 239000003242 anti bacterial agent Substances 0.000 claims 3
- 229940088710 antibiotic agent Drugs 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 230000006907 apoptotic process Effects 0.000 claims 3
- 229960000397 bevacizumab Drugs 0.000 claims 3
- 210000000988 bone and bone Anatomy 0.000 claims 3
- 210000004556 brain Anatomy 0.000 claims 3
- 210000000481 breast Anatomy 0.000 claims 3
- 229960001265 ciclosporin Drugs 0.000 claims 3
- 229960003405 ciprofloxacin Drugs 0.000 claims 3
- 239000003246 corticosteroid Substances 0.000 claims 3
- 229960001334 corticosteroids Drugs 0.000 claims 3
- 229930182912 cyclosporin Natural products 0.000 claims 3
- 229960003901 dacarbazine Drugs 0.000 claims 3
- 229960003957 dexamethasone Drugs 0.000 claims 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 3
- 229960004679 doxorubicin Drugs 0.000 claims 3
- 229960001776 edrecolomab Drugs 0.000 claims 3
- 229940121647 egfr inhibitor Drugs 0.000 claims 3
- GTTBEUCJPZQMDZ-UHFFFAOYSA-N erlotinib hydrochloride Chemical compound [H+].[Cl-].C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 GTTBEUCJPZQMDZ-UHFFFAOYSA-N 0.000 claims 3
- 229960005073 erlotinib hydrochloride Drugs 0.000 claims 3
- 229960000403 etanercept Drugs 0.000 claims 3
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 3
- 229960002584 gefitinib Drugs 0.000 claims 3
- 239000003102 growth factor Substances 0.000 claims 3
- 230000003394 haemopoietic effect Effects 0.000 claims 3
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 claims 3
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 3
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 3
- 239000002955 immunomodulating agent Substances 0.000 claims 3
- 229940121354 immunomodulator Drugs 0.000 claims 3
- 229960003444 immunosuppressant agent Drugs 0.000 claims 3
- 239000003018 immunosuppressive agent Substances 0.000 claims 3
- 239000000411 inducer Substances 0.000 claims 3
- 229940125396 insulin Drugs 0.000 claims 3
- 229960004768 irinotecan Drugs 0.000 claims 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 3
- 229960005280 isotretinoin Drugs 0.000 claims 3
- 230000003211 malignant effect Effects 0.000 claims 3
- 230000001394 metastastic effect Effects 0.000 claims 3
- 206010061289 metastatic neoplasm Diseases 0.000 claims 3
- 201000008482 osteoarthritis Diseases 0.000 claims 3
- 229960001476 pentoxifylline Drugs 0.000 claims 3
- 229960002087 pertuzumab Drugs 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 229960004641 rituximab Drugs 0.000 claims 3
- 229950003647 semaxanib Drugs 0.000 claims 3
- WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 claims 3
- 230000035939 shock Effects 0.000 claims 3
- -1 statin Substances 0.000 claims 3
- 229940063683 taxotere Drugs 0.000 claims 3
- YVSQVYZBDXIXCC-INIZCTEOSA-N telomestatin Chemical compound N=1C2=COC=1C(N=1)=COC=1C(N=1)=COC=1C(N=1)=COC=1C(N=1)=COC=1C(=C(O1)C)N=C1C(=C(O1)C)N=C1[C@@]1([H])N=C2SC1 YVSQVYZBDXIXCC-INIZCTEOSA-N 0.000 claims 3
- 229960000303 topotecan Drugs 0.000 claims 3
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 3
- 229960005267 tositumomab Drugs 0.000 claims 3
- 239000003053 toxin Substances 0.000 claims 3
- 231100000765 toxin Toxicity 0.000 claims 3
- 229960000575 trastuzumab Drugs 0.000 claims 3
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 claims 3
- 229960004528 vincristine Drugs 0.000 claims 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 3
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 3
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims 3
- 229960002066 vinorelbine Drugs 0.000 claims 3
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 claims 3
- QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 claims 3
- 206010068532 5q minus syndrome Diseases 0.000 claims 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 206010001257 Adenoviral conjunctivitis Diseases 0.000 claims 2
- 206010002064 Anaemia macrocytic Diseases 0.000 claims 2
- 208000031104 Arterial Occlusive disease Diseases 0.000 claims 2
- 206010003571 Astrocytoma Diseases 0.000 claims 2
- 206010003645 Atopy Diseases 0.000 claims 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims 2
- 208000009137 Behcet syndrome Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006143 Brain stem glioma Diseases 0.000 claims 2
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 2
- 208000002691 Choroiditis Diseases 0.000 claims 2
- 206010011686 Cutaneous vasculitis Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 claims 2
- 208000019878 Eales disease Diseases 0.000 claims 2
- 201000009273 Endometriosis Diseases 0.000 claims 2
- 208000037487 Endotoxemia Diseases 0.000 claims 2
- 201000001342 Fallopian tube cancer Diseases 0.000 claims 2
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims 2
- 206010016935 Follicular thyroid cancer Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 208000009889 Herpes Simplex Diseases 0.000 claims 2
- 208000007514 Herpes zoster Diseases 0.000 claims 2
- 201000002563 Histoplasmosis Diseases 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 208000037147 Hypercalcaemia Diseases 0.000 claims 2
- 206010051151 Hyperviscosity syndrome Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 208000016604 Lyme disease Diseases 0.000 claims 2
- 206010026673 Malignant Pleural Effusion Diseases 0.000 claims 2
- 208000009018 Medullary thyroid cancer Diseases 0.000 claims 2
- 201000009906 Meningitis Diseases 0.000 claims 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 208000028606 Optic disc pit Diseases 0.000 claims 2
- 208000010191 Osteitis Deformans Diseases 0.000 claims 2
- 208000027868 Paget disease Diseases 0.000 claims 2
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims 2
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 claims 2
- 208000003971 Posterior uveitis Diseases 0.000 claims 2
- 201000002154 Pterygium Diseases 0.000 claims 2
- 206010038019 Rectal adenocarcinoma Diseases 0.000 claims 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims 2
- 206010038848 Retinal detachment Diseases 0.000 claims 2
- 206010038910 Retinitis Diseases 0.000 claims 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 2
- 241001303601 Rosacea Species 0.000 claims 2
- 206010039705 Scleritis Diseases 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 208000004346 Smoldering Multiple Myeloma Diseases 0.000 claims 2
- 208000027073 Stargardt disease Diseases 0.000 claims 2
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims 2
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 2
- 201000005485 Toxoplasmosis Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 206010046851 Uveitis Diseases 0.000 claims 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 2
- 206010000496 acne Diseases 0.000 claims 2
- 208000019269 advanced heart failure Diseases 0.000 claims 2
- 206010002022 amyloidosis Diseases 0.000 claims 2
- 206010002224 anaplastic astrocytoma Diseases 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 208000021328 arterial occlusion Diseases 0.000 claims 2
- 239000010425 asbestos Substances 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 210000004204 blood vessel Anatomy 0.000 claims 2
- 210000003679 cervix uteri Anatomy 0.000 claims 2
- 230000005796 circulatory shock Effects 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 2
- 230000007850 degeneration Effects 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 210000004177 elastic tissue Anatomy 0.000 claims 2
- 210000004696 endometrium Anatomy 0.000 claims 2
- 208000021373 epidemic keratoconjunctivitis Diseases 0.000 claims 2
- 210000003238 esophagus Anatomy 0.000 claims 2
- 210000001508 eye Anatomy 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 230000002538 fungal effect Effects 0.000 claims 2
- 208000007565 gingivitis Diseases 0.000 claims 2
- 210000003128 head Anatomy 0.000 claims 2
- 208000029824 high grade glioma Diseases 0.000 claims 2
- 208000018821 hormone-resistant prostate carcinoma Diseases 0.000 claims 2
- 230000000148 hypercalcaemia Effects 0.000 claims 2
- 208000030915 hypercalcemia disease Diseases 0.000 claims 2
- 201000001371 inclusion conjunctivitis Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 230000035984 keratolysis Effects 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 201000006370 kidney failure Diseases 0.000 claims 2
- 201000010260 leiomyoma Diseases 0.000 claims 2
- 230000004130 lipolysis Effects 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 210000001165 lymph node Anatomy 0.000 claims 2
- 201000006437 macrocytic anemia Diseases 0.000 claims 2
- 201000011614 malignant glioma Diseases 0.000 claims 2
- 208000006178 malignant mesothelioma Diseases 0.000 claims 2
- 208000027202 mammary Paget disease Diseases 0.000 claims 2
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims 2
- 206010027191 meningioma Diseases 0.000 claims 2
- 208000021039 metastatic melanoma Diseases 0.000 claims 2
- 208000010658 metastatic prostate carcinoma Diseases 0.000 claims 2
- 210000000214 mouth Anatomy 0.000 claims 2
- 201000005962 mycosis fungoides Diseases 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 208000001491 myopia Diseases 0.000 claims 2
- 230000004379 myopia Effects 0.000 claims 2
- 201000003142 neovascular glaucoma Diseases 0.000 claims 2
- 210000004412 neuroendocrine cell Anatomy 0.000 claims 2
- 230000000683 nonmetastatic effect Effects 0.000 claims 2
- 230000000414 obstructive effect Effects 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 2
- 201000005163 papillary serous adenocarcinoma Diseases 0.000 claims 2
- 201000001245 periodontitis Diseases 0.000 claims 2
- 201000002628 peritoneum cancer Diseases 0.000 claims 2
- 210000004786 perivascular cell Anatomy 0.000 claims 2
- 210000003800 pharynx Anatomy 0.000 claims 2
- 238000010837 poor prognosis Methods 0.000 claims 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- 208000028172 protozoa infectious disease Diseases 0.000 claims 2
- 210000000664 rectum Anatomy 0.000 claims 2
- 201000001281 rectum adenocarcinoma Diseases 0.000 claims 2
- 230000010076 replication Effects 0.000 claims 2
- 230000004264 retinal detachment Effects 0.000 claims 2
- 230000001177 retroviral effect Effects 0.000 claims 2
- 229910052895 riebeckite Inorganic materials 0.000 claims 2
- 201000004700 rosacea Diseases 0.000 claims 2
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 2
- 201000006476 shipyard eye Diseases 0.000 claims 2
- 208000007056 sickle cell anemia Diseases 0.000 claims 2
- 239000000377 silicon dioxide Substances 0.000 claims 2
- 210000003491 skin Anatomy 0.000 claims 2
- 201000009295 smoldering myeloma Diseases 0.000 claims 2
- 208000010721 smoldering plasma cell myeloma Diseases 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- 208000006379 syphilis Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 210000001550 testis Anatomy 0.000 claims 2
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 claims 2
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 206010044325 trachoma Diseases 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 210000003932 urinary bladder Anatomy 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 210000004291 uterus Anatomy 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 206010002329 Aneurysm Diseases 0.000 claims 1
- 206010061692 Benign muscle neoplasm Diseases 0.000 claims 1
- 208000037663 Best vitelliform macular dystrophy Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 206010063094 Cerebral malaria Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 108010092408 Eosinophil Peroxidase Proteins 0.000 claims 1
- 102100028471 Eosinophil peroxidase Human genes 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 208000018142 Leiomyosarcoma Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010059282 Metastases to central nervous system Diseases 0.000 claims 1
- 201000004458 Myoma Diseases 0.000 claims 1
- 206010034277 Pemphigoid Diseases 0.000 claims 1
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000009527 Refractory anemia Diseases 0.000 claims 1
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010038934 Retinopathy proliferative Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 claims 1
- 206010058990 Venous occlusion Diseases 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 210000000038 chest Anatomy 0.000 claims 1
- 201000010064 diabetes insipidus Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000002491 encephalomyelitis Diseases 0.000 claims 1
- 208000003401 eosinophilic granuloma Diseases 0.000 claims 1
- 239000011521 glass Substances 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 230000011164 ossification Effects 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 230000000392 somatic effect Effects 0.000 claims 1
- 230000007704 transition Effects 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
- 201000007790 vitelliform macular dystrophy Diseases 0.000 claims 1
- 208000020938 vitelliform macular dystrophy 2 Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/900,332 US7405237B2 (en) | 2004-07-28 | 2004-07-28 | Isoindoline compounds and methods of their use |
| PCT/US2005/026679 WO2006015060A2 (en) | 2004-07-28 | 2005-07-27 | Isoindoline compounds and methods of their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008508298A JP2008508298A (ja) | 2008-03-21 |
| JP2008508298A5 true JP2008508298A5 (OSRAM) | 2009-02-12 |
Family
ID=35733185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007523776A Pending JP2008508298A (ja) | 2004-07-28 | 2005-07-27 | イソインドリン化合物及びそれらの使用法 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US7405237B2 (OSRAM) |
| EP (1) | EP1781610A2 (OSRAM) |
| JP (1) | JP2008508298A (OSRAM) |
| KR (1) | KR20070047807A (OSRAM) |
| CN (1) | CN101031545A (OSRAM) |
| AU (1) | AU2005269367B2 (OSRAM) |
| BR (1) | BRPI0513836A (OSRAM) |
| CA (1) | CA2574966A1 (OSRAM) |
| IL (1) | IL180978A0 (OSRAM) |
| MX (1) | MX2007000842A (OSRAM) |
| NZ (1) | NZ553029A (OSRAM) |
| WO (1) | WO2006015060A2 (OSRAM) |
| ZA (1) | ZA200701660B (OSRAM) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7842691B2 (en) * | 2002-10-15 | 2010-11-30 | Celgene Corporation | Method for the treatment of myelodysplastic syndromes using cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-OXO-2,3-dihydro-1 H-isoindol-4-yl}-amide |
| US20060165649A1 (en) * | 2002-11-06 | 2006-07-27 | Zeldis Jerome B | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases |
| CN1972686A (zh) * | 2004-04-14 | 2007-05-30 | 细胞基因公司 | 选择性细胞因子抑制药在髓发育不良综合征中的用途 |
| US7405237B2 (en) * | 2004-07-28 | 2008-07-29 | Celgene Corporation | Isoindoline compounds and methods of their use |
| US7244759B2 (en) * | 2004-07-28 | 2007-07-17 | Celgene Corporation | Isoindoline compounds and methods of making and using the same |
| US9233094B2 (en) * | 2005-05-04 | 2016-01-12 | Medigene Ag | Method of administering a cationic liposomal preparation |
| JP5366544B2 (ja) | 2005-06-30 | 2013-12-11 | セルジーン コーポレイション | ４−アミノ−２−（２，６−ジオキソピペリジン−３−イル）イソインドリン−１，３−ジオン化合物を調製するための方法 |
| AU2007228984B2 (en) | 2006-03-22 | 2012-05-03 | Syncore Biotechnology Co., Ltd | Treatment of triple receptor negative breast cancer |
| US20080064876A1 (en) * | 2006-05-16 | 2008-03-13 | Muller George W | Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione |
| TW200806625A (en) * | 2006-05-26 | 2008-02-01 | Astrazeneca Ab | Therapeutic compounds |
| US20090082368A1 (en) * | 2007-09-24 | 2009-03-26 | Painceptor Pharma Corporation | Methods of modulating neurotrophin-mediated activity |
| MY160002A (en) | 2009-02-10 | 2017-02-15 | Celgene Corp | Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis |
| WO2010131193A1 (en) * | 2009-05-12 | 2010-11-18 | Koninklijke Philips Electronics N.V. | Phosphodiesterase 9a as prostate cancer marker |
| CN101580501B (zh) * | 2009-06-01 | 2011-03-09 | 南京卡文迪许生物工程技术有限公司 | 3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮的合成方法及其中间体 |
| AU2010290822A1 (en) * | 2009-09-03 | 2012-03-29 | Ranbaxy Laboratories Limited | Process for the preparation of lenalidomide |
| GB2474120B (en) * | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
| CN101747255B (zh) * | 2009-12-22 | 2011-11-23 | 上海大学 | 含烯炔结构的异吲哚酮类化合物及其合成方法 |
| SG10201501062SA (en) | 2010-02-11 | 2015-04-29 | Celgene Corp | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| CN103026229B (zh) | 2010-06-15 | 2016-03-30 | 细胞基因公司 | 用于治疗银屑病的生物标志物 |
| CN102603610B (zh) * | 2012-02-21 | 2014-07-09 | 四川大学 | 1,3-二氢-1-氧-2h-异吲哚类化合物、其制备方法和用途 |
| CN104045594B (zh) * | 2012-02-21 | 2016-08-17 | 四川大学 | 一类1,3-二氢-1-氧-2h-异吲哚类化合物及其用途 |
| KR101441096B1 (ko) * | 2012-11-27 | 2014-09-25 | 가톨릭대학교 산학협력단 | 제피티닙을 포함하는 톡소포자충 감염증의 예방 및 치료용 조성물 |
| EP2986318A1 (en) | 2013-04-17 | 2016-02-24 | Signal Pharmaceuticals, LLC | Combination therapy comprising a tor kinase inhibitor and an imid compound for treating cancer |
| CN104721820A (zh) * | 2013-12-24 | 2015-06-24 | 信达生物制药(苏州)有限公司 | 双特异性单克隆抗体在治疗葡萄膜炎中的用途 |
| US20170087129A1 (en) | 2014-05-16 | 2017-03-30 | Celgene Corporation | Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators |
| LT3166925T (lt) * | 2014-07-08 | 2018-06-11 | Viiv Healthcare Uk Limited | Izoindolino dariniai, skirti panaudoti virusinės infekcijos gydymui |
| WO2017015484A1 (en) | 2015-07-23 | 2017-01-26 | Temple University-Of The Commonwealth System Of Higher Education | Novel aminothiazole compounds and methods using same |
| WO2017070291A1 (en) | 2015-10-21 | 2017-04-27 | Celgene Corporation | Pde4 modulators for treating and preventing immune reconstitution inflammatory syndrome (iris) |
| WO2018136766A1 (en) * | 2017-01-19 | 2018-07-26 | Temple University-Of The Commonwealth System Of Higher Education | Novel bridged bicycloalkyl-substituted aminothizoles and their methods of use |
| WO2019040109A1 (en) | 2017-08-21 | 2019-02-28 | Celgene Corporation | PROCESSES FOR THE PREPARATION OF (S) -TERT-BUTYL 4,5-DIAMINO-5-OXOPENTANOATE |
| EP3838898B1 (en) * | 2018-08-16 | 2023-06-07 | Korea Research Institute of Chemical Technology | Isoindolin-1-one derivative, method for preparing the same, and pharmaceutical composition comprising the same as an effective component for preventing or treating cancer |
| AU2020412805A1 (en) * | 2019-12-26 | 2022-07-14 | Hendrix College | Methods and compositions for inhibition of dihydroorotate dehydrogenase in combination with an anti-CD38 therapeutic agent |
| CN114644586A (zh) * | 2022-04-12 | 2022-06-21 | 江苏豪森药业集团有限公司 | 一种来那度胺有关物质的制备方法 |
| WO2025118133A1 (zh) * | 2023-12-05 | 2025-06-12 | 浙江普洛家园药业有限公司 | 一种(s)-来那度胺-5-位衍生物及其合成方法和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001511448A (ja) | 1997-07-31 | 2001-08-14 | セルジーン コーポレイション | 置換アルカノヒドロキサム酸およびＴＮＦαレベルの減少方法 |
| CA2361806C (en) * | 1999-03-18 | 2012-03-13 | Celgene Corporation | Substituted 1-oxo- and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels |
| US6326388B1 (en) * | 1999-12-21 | 2001-12-04 | Celgene Corporation | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level |
| NZ531294A (en) | 2001-08-06 | 2005-11-25 | Childrens Medical Center | Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs |
| US7405237B2 (en) * | 2004-07-28 | 2008-07-29 | Celgene Corporation | Isoindoline compounds and methods of their use |
-
2004
- 2004-07-28 US US10/900,332 patent/US7405237B2/en active Active
-
2005
- 2005-07-27 ZA ZA200701660A patent/ZA200701660B/xx unknown
- 2005-07-27 BR BRPI0513836-1A patent/BRPI0513836A/pt not_active IP Right Cessation
- 2005-07-27 MX MX2007000842A patent/MX2007000842A/es active IP Right Grant
- 2005-07-27 KR KR1020077004729A patent/KR20070047807A/ko not_active Ceased
- 2005-07-27 JP JP2007523776A patent/JP2008508298A/ja active Pending
- 2005-07-27 NZ NZ553029A patent/NZ553029A/en not_active IP Right Cessation
- 2005-07-27 CN CNA2005800327224A patent/CN101031545A/zh active Pending
- 2005-07-27 WO PCT/US2005/026679 patent/WO2006015060A2/en not_active Ceased
- 2005-07-27 CA CA002574966A patent/CA2574966A1/en not_active Abandoned
- 2005-07-27 AU AU2005269367A patent/AU2005269367B2/en not_active Expired
- 2005-07-27 EP EP05775526A patent/EP1781610A2/en not_active Withdrawn
-
2007
- 2007-01-25 IL IL180978A patent/IL180978A0/en unknown
-
2008
- 2008-02-15 US US12/070,322 patent/US7569597B2/en not_active Expired - Lifetime
-
2009
- 2009-08-04 US US12/535,642 patent/US7816393B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6026441B2 (ja) | キナーゼ阻害剤としてのアミノキノリン | |
| US6608053B2 (en) | Fused heteroaryl derivatives | |
| US6642228B1 (en) | α1b-adrenergic receptor antagonists | |
| WO2002094809A1 (fr) | Derives de 3-quinoleine-2-(1h)-ylideneindoline-2-one | |
| ES2313991T3 (es) | Derivados de 6-heterociclilmetil-quinolina y quinazolina que inhiben la farnesil transferasa. | |
| JP5585892B2 (ja) | キナーゼ阻害剤としての化合物 | |
| RU2010128107A (ru) | Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp | |
| CA2831937A1 (en) | Combinations of akt inhibitor compounds and erlotinib, and methods of use | |
| CA2486141A1 (en) | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases | |
| JP2007510670A5 (OSRAM) | ||
| BR112021005091A2 (pt) | heterociclos funcionalizados como agentes antivirais | |
| JP2006508131A5 (OSRAM) | ||
| US9012659B2 (en) | 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment | |
| US20040116497A1 (en) | Chromane derivatives, process for their preparation and their use as antitumor agents | |
| WO2024251080A1 (zh) | 3,4-二氢酞嗪-1(2h)-酮类衍生物及其制备方法和用途 | |
| WO1995009167A1 (en) | Indoline derivative and 5-ht3 receptor antagonist containing the same as active ingredient | |
| RU2165420C2 (ru) | 1,2,5-тиадиазольные производные индолилалкил-пиримидинил-пиперазинов и фармацевтическая композиция на их основе | |
| TWI753229B (zh) | 用於治療癌症之組合療法 | |
| WO2006077851A1 (ja) | キノロン誘導体又はその塩 | |
| US20040097539A1 (en) | Hsp inductor | |
| JP2024534044A (ja) | Ｄｄｒ１の阻害剤としてのフェニルおよびピリドピラゾール誘導体 | |
| JP4351444B2 (ja) | ファルネシルトランスフェラーゼを阻害する４−ヘテロシクリル−キノリンおよびキナゾリン誘導体 | |
| US20240190827A1 (en) | Inhibitors of Rho Associated Coiled-Coil Containing Protein Kinase | |
| CN114364683A (zh) | 芳香杂环衍生物作为免疫调节剂的制备及其应用 | |
| JP2007518791A (ja) | オンダンセトロンの新規多形体、該多形体の製造方法、該多形体を含有する医薬組成物、および抗嘔吐剤としての該多形体の使用 |